ABIVAX Société Anonyme (ABVX) Competitors

ABIVAX Société Anonyme (NASDAQ:ABVX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Is ABVX or ARQT more profitable?

ABIVAX Société Anonyme has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. ABIVAX Société Anonyme's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABIVAX Société Anonyme	N/A	N/A	N/A
Arcutis Biotherapeutics	-140.97%	-119.11%	-45.95%

Does the MarketBeat Community believe in ABVX or ARQT?

Arcutis Biotherapeutics received 63 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 76.92% of users gave ABIVAX Société Anonyme an outperform vote while only 68.22% of users gave Arcutis Biotherapeutics an outperform vote.

Company	Underperform	Outperform
ABIVAX Société Anonyme	Outperform Votes 10 76.92%	Underperform Votes 3 23.08%
Arcutis Biotherapeutics	Outperform Votes 73 68.22%	Underperform Votes 34 31.78%

Do institutionals & insiders hold more shares of ABVX or ARQT?

47.9% of ABIVAX Société Anonyme shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend ABVX or ARQT?

ABIVAX Société Anonyme currently has a consensus target price of $31.00, suggesting a potential upside of 334.78%. Arcutis Biotherapeutics has a consensus target price of $18.80, suggesting a potential upside of 38.95%. Given ABIVAX Société Anonyme's stronger consensus rating and higher possible upside, analysts clearly believe ABIVAX Société Anonyme is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABIVAX Société Anonyme	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Arcutis Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the media refer more to ABVX or ARQT?

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 6 mentions for ABIVAX Société Anonyme. Arcutis Biotherapeutics' average media sentiment score of 0.93 beat ABIVAX Société Anonyme's score of 0.55 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABIVAX Société Anonyme	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, ABVX or ARQT?

ABIVAX Société Anonyme has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.

Which has better earnings and valuation, ABVX or ARQT?

ABIVAX Société Anonyme has higher earnings, but lower revenue than Arcutis Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABIVAX Société Anonyme	N/A	N/A	-$159.90M	N/A	N/A
Arcutis Biotherapeutics	$212.82M	7.58	-$262.14M	-$1.04	-13.01

Summary

ABIVAX Société Anonyme beats Arcutis Biotherapeutics on 9 of the 16 factors compared between the two stocks.